Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Akebia, Astrazeneca, Beigene, Chiesi, Daiichi Sankyo, Incyte, Janssen, Merck, Protalix, Regeneron, Ridgeback, Servier, Sobi, Timber.
Global Health Drug Discovery Institute (GHDDI) has presented 3C-like proteinase (3CLpro) (SARS-CoV-2) inhibitors reported to be useful for the treatment of Middle East respiratory syndrome coronavirus (MERS-CoV), severe acute respiratory syndrome coronavirus (SARS-CoV) and SARS-CoV-2 infections (COVID-19).
Researchers from PDS Biotechnology Corp. and affiliated organizations have detailed the development and preclinical evaluation of recombinant protein vaccines formulated with enantio-specific cationic lipid R-DOTAP.
Insilico Medicine Inc. has received IND clearance from China's National Medical Products Administration (NMPA) for ISM-3312, an orally available 3CLpro inhibitor for the treatment of COVID-19. ISM-3312 has a novel molecular structure and was optimized from compounds designed by Chemistry42, Insilico’s generative chemistry AI platform.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Adial, Alimera, Cognition, Erydel, Fapon, GSK, Pfizer, PTC, Sage, Seagen, Viiv, Vir.